Telix Pharmaceuticals (TLX1N) Ratios
Telix Pharmaceuticals Ratios
MX:TLX1N's free cash flow for Q2 2026 was $3.99M. For the 2026 fiscal year, MX:TLX1N's free cash flow was decreased by $-18.59M and operating cash flow was $22.58M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.43 | 2.78 | 1.48 | 2.02 | 1.25 |
| Quick Ratio | 1.27 | 2.66 | 1.37 | 1.93 | 1.16 |
| Cash Ratio | 0.61 | 2.15 | 0.78 | 1.36 | 0.58 |
| Solvency Ratio | 0.02 | 0.06 | 0.05 | -0.55 | -0.71 |
| Operating Cash Flow Ratio | -0.08 | 0.13 | 0.15 | -0.75 | -1.56 |
| Short-Term Operating Cash Flow Coverage | -1.34 | 2.27 | 24.78 | -99.80 | -3122.53 |
| Net Current Asset Value | $ -436.75M | $ -29.65M | $ -16.89M | $ -5.20M | $ -58.63M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.39 | 0.38 | 0.04 | 0.04 | 0.02 |
| Debt-to-Equity Ratio | 1.12 | 1.02 | 0.12 | 0.13 | 1.18 |
| Debt-to-Capital Ratio | 0.53 | 0.51 | 0.10 | 0.12 | 0.54 |
| Long-Term Debt-to-Capital Ratio | 0.49 | 0.49 | 0.05 | 0.04 | 0.00 |
| Financial Leverage Ratio | 2.85 | 2.67 | 2.67 | 3.19 | 50.89 |
| Debt Service Coverage Ratio | 0.76 | 2.01 | 12.79 | -93.88 | -247.81 |
| Interest Coverage Ratio | 0.48 | 3.83 | 51.99 | -180.25 | -429.88 |
| Debt to Market Cap | 0.11 | 0.07 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 1.49 | 1.82 | 0.06 | 0.03 | 0.01 |
| Net Debt to EBITDA | 8.09 | -1.47 | -4.61 | 1.14 | 0.28 |
| Profitability Margins | |||||
| Gross Profit Margin | 53.11% | 65.08% | 62.56% | 18.32% | -391.85% |
| EBIT Margin | 2.21% | 10.46% | 3.23% | -61.35% | -990.61% |
| EBITDA Margin | 4.92% | 11.18% | 4.57% | -57.99% | -922.50% |
| Operating Profit Margin | 2.21% | 10.49% | 10.32% | -45.71% | -1069.60% |
| Pretax Profit Margin | -0.66% | 7.16% | 0.61% | -61.60% | -1303.83% |
| Net Profit Margin | -0.89% | 6.37% | 1.04% | -65.01% | -1059.90% |
| Continuous Operations Profit Margin | -0.89% | 6.37% | 1.04% | -65.01% | -1059.90% |
| Net Income Per EBT | 135.30% | 89.05% | 168.80% | 105.53% | 81.29% |
| EBT Per EBIT | -29.64% | 68.25% | 5.95% | 134.77% | 121.90% |
| Return on Assets (ROA) | -0.61% | 3.29% | 1.31% | -40.76% | -73.32% |
| Return on Equity (ROE) | -1.74% | 8.79% | 3.50% | -130.09% | -3730.77% |
| Return on Capital Employed (ROCE) | 1.90% | 6.93% | 21.54% | -43.10% | -113.11% |
| Return on Invested Capital (ROIC) | 1.86% | 6.06% | 20.75% | -41.50% | -91.15% |
| Return on Tangible Assets | -1.23% | 4.54% | 1.81% | -54.53% | -161.06% |
| Earnings Yield | -0.19% | 0.61% | 0.16% | -4.61% | -3.68% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.90 | 4.93 | 6.32 | 3.49 | 0.36 |
| Payables Turnover | 5.34 | 3.98 | 5.73 | 7.78 | 3.14 |
| Inventory Turnover | 10.32 | 7.17 | 10.87 | 15.43 | 10.82 |
| Fixed Asset Turnover | 7.06 | 14.42 | 16.48 | 8.50 | 1.20 |
| Asset Turnover | 0.69 | 0.52 | 1.26 | 0.63 | 0.07 |
| Working Capital Turnover Ratio | 2.38 | 2.36 | 6.17 | 3.29 | 0.18 |
| Cash Conversion Cycle | 28.90 | 33.32 | 27.65 | 81.44 | 919.28 |
| Days of Sales Outstanding | 61.88 | 74.10 | 57.77 | 104.69 | 1001.64 |
| Days of Inventory Outstanding | 35.37 | 50.90 | 33.58 | 23.66 | 33.74 |
| Days of Payables Outstanding | 68.35 | 91.67 | 63.70 | 46.91 | 116.10 |
| Operating Cycle | 97.25 | 125.00 | 91.35 | 128.35 | 1035.38 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.05 | 0.13 | 0.07 | -0.21 | -0.21 |
| Free Cash Flow Per Share | -0.17 | 0.03 | 0.04 | -0.25 | -0.21 |
| Dividend Paid and CapEx Coverage Ratio | -0.46 | 1.26 | 2.21 | -4.62 | -44.31 |
| Capital Expenditure Coverage Ratio | -0.46 | 1.26 | 2.21 | -4.62 | -44.31 |
| Operating Cash Flow Coverage Ratio | -0.04 | 0.07 | 1.37 | -6.12 | -23.37 |
| Operating Cash Flow to Sales Ratio | -0.02 | 0.05 | 0.05 | -0.40 | -7.81 |
| Free Cash Flow Yield | -1.48% | 0.11% | 0.41% | -3.45% | -2.77% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -523.36 | 164.07 | 617.41 | -21.70 | -27.17 |
| Price-to-Sales (P/S) Ratio | 4.63 | 10.41 | 6.40 | 14.11 | 287.93 |
| Price-to-Book (P/B) Ratio | 9.10 | 14.35 | 21.61 | 28.23 | 1013.48 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -67.46 | 906.02 | 245.79 | -29.02 | -36.05 |
| Price-to-Operating Cash Flow Ratio | -215.37 | 189.44 | 134.71 | -35.30 | -36.86 |
| Price-to-Earnings Growth (PEG) Ratio | 4.58 | 0.20 | -5.88 | -1.57 | -0.38 |
| Enterprise Value Multiple | 102.26 | 91.60 | 135.49 | -23.19 | -30.93 |
| Enterprise Value | 4.11B | 8.02B | 3.11B | 2.15B | 2.17B |
| EV to EBITDA | 102.26 | 91.60 | 135.49 | -23.19 | -30.93 |
| EV to Sales | 5.03 | 10.24 | 6.19 | 13.45 | 285.36 |
| EV to Free Cash Flow | -73.25 | 891.69 | 237.70 | -27.66 | -35.73 |
| EV to Operating Cash Flow | -233.87 | 186.45 | 130.28 | -33.65 | -36.54 |
| Tangible Book Value Per Share | -0.53 | 0.46 | 0.12 | 0.04 | -0.20 |
| Shareholders’ Equity Per Share | 1.23 | 1.72 | 0.47 | 0.26 | 0.01 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.35 | 0.11 | -0.69 | -0.06 | 0.19 |
| Revenue Per Share | 2.42 | 2.36 | 1.57 | 0.52 | 0.03 |
| Net Income Per Share | -0.02 | 0.15 | 0.02 | -0.34 | -0.29 |
| Tax Burden | 1.35 | 0.89 | 1.69 | 1.06 | 0.81 |
| Interest Burden | -0.30 | 0.68 | 0.19 | 1.00 | 1.32 |
| Research & Development to Revenue | 0.21 | 0.25 | 0.26 | 0.36 | 4.49 |
| SG&A to Revenue | 0.29 | 0.30 | 0.16 | 0.31 | 4.60 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.02 | 0.05 | 0.17 |
| Income Quality | 2.43 | 0.86 | 4.58 | 0.61 | 0.74 |
Currency in AUD
